You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《藍籌業績》石藥集團(01093.HK)首三季純利35.18億元人民幣升25.1%
阿思達克 11-23 12:00
石藥集團(01093.HK)公布截至今年9月底止首三季業績,營業額192.15億元人民幣(下同),按年升14.6%。純利35.18億元,按年升25.1%;每股盈利29.43分。

期內,成藥業務錄得銷售收入人民幣157.13億元,較去年同期增加17.4%。其中,神經系統疾病產品錄得銷售收入59.87億元,增加9.6%。抗腫瘤產品錄得銷售收入47.17億元,增加35.4%。,抗感染產品錄得銷售收入20.43億元,減少13.8%。心血管疾病產品錄得銷售收入17.62億元,增加68%。

維生素C原料業務於本期錄得銷售收入14.38億元,較去年同期減少9.9%。受疫情影響,產品價格於第二季借勢上漲,出口量創歷史新高,惟隨著出口市場需求放緩,產品價格於第三季相應回落。

抗生素原料業務於本期錄得銷售收入7.62億元,較去年同期增加6.6%。期內市場需求平穩,產品價格略微回升。

集團今年以來申請專利129件,其中國內申請96件,國外申請33件;取得專利授權90件,其中國內授權75件,國外授權15件。未來三年,集團預計將上市新產品50餘個,其中預計市場空間超過10億元的重磅品種將不少於15個,可強力支持集團未來的高質量增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account